BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, **FAX**: 91-44-25231264, **Email**: info@bafnapharma.com, **Website**: www.bafnapharma.com
CIN:L24294TN1995PLCO30698

Date: August 11, 2026

To

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001.	**National Stock Exchange of India Limited,** Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai – 400051.
Scrip Code: 532989	Scrip Code: BAFNAPH

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on August 11, 2026 under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors in their meeting held Today (i.e) August 11, 2026, inter-alia considered and approved the following:

i). The Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors of the Company, for the First Quarter ended June 30, 2026 as recommended by the Audit Committee. Accordingly, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Unaudited Financial Results of the Company for the quarter ended June 30, 2026 along with the Limited Review Report, are enclosed herewith.

ii). **Annual General Meeting**: The 31st Annual General Meeting (AGM) of the Company will be held on **Friday, September 11, 2026, at 10:00 A.M (IST)** through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).

iii). **Book Closure**: The Register of Members and Share Transfer Books of the company will remain closed from **Saturday, September 05, 2026** to **Friday, September 11, 2026** (both days inclusive), pursuant to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 iv). **Cut-Off Date**: The Cut-Off date for the purpose of determining eligibility of members for voting at the 31st AGM shall be **Friday, September 04, 2026**.

The Meeting of the Board of Directors commenced at 02.30 P.M and concluded at 04.00 P.M.

We request you to take the documents and information on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

MOHANACHANDRAN A Digitally signed by MOHANACHANDRAN A Date: 2026.08.11 17:47:26 +05'30'

Mohanachandran A
Company Secretary & Compliance Officer

Enclosed: As Above

BAFNA PHARMACEUTICALS LTD

CIN: L24294TN1995PLC030698

Corporate Office and Registered Office: Bafna Towers, New No. 68, Old No 299, Tambu Chetty Street, Chennai-600001 (Tamil Nadu)

Email : cs@bafnapharma.com, Web : www.bafnapharma.com

Statement of unaudited Financial Results for the Quarter Ended 30th June 2026

(INR in Lakhs except as Stated)

	Particulars	Quarter Ended			Year Ended
		30th June 2026 (Unaudited)	31st March 2026 (Audited)	30th June 2025 (Unaudited)	31st March 2026 (Audited)
1	Revenue from Operations	2,658.32	4,223.93	3,462.40	15,061.74
	Other Income	191.10	176.16	59.56	475.63
2	**Total Income**	**2,849.42**	**4,400.09**	**3,521.96**	**15,537.37**
	EXPENSES				
	Cost of Material Consumed	1,431.50	2,139.30	1,755.78	8,213.53
	Manufacturing Expenses	488.75	537.28	507.96	2,050.82
	Change in Inventories of Work-in-Progress and Finished Goods	(170.44)	297.11	(21.96)	(15.96)
	Employee benefits expenses	561.63	544.33	563.99	2,191.89
	Finance cost	93.70	102.90	90.54	366.11
	Depreciation and Amortization expense	178.07	165.99	136.99	607.26
	Other expenses	258.70	351.23	149.77	1,026.70
3	**Total Expenses**	**2,841.91**	**4,138.14**	**3,183.07**	**14,440.35**
4	**Profit/(Loss) before Exceptional Items & tax (2-3)**	**7.51**	**261.95**	**338.89**	**1,097.02**
5	**Exceptional Items**	-	-	-	-
6	**Profit / (Loss) before Tax (4-5)**	**7.51**	**261.95**	**338.89**	**1,097.02**
7	**Tax Expense**				
	- Relating to Previous Periods	-	(12.96)	-	(12.96)
8	**Profit / (Loss) for the Period (6-7)**	**7.51**	**274.91**	**338.89**	**1,109.98**
9	Other Comprehensive Income	6.08	38.20	(4.62)	24.33
10	**Total Comprehensive Income for the period (8+9)**	**13.59**	**313.11**	**334.27**	**1,134.31**
11	**Paid up Share Capital (Face Value of INR 10 each)**	**2,365.63**	**2,365.63**	**2,365.63**	**2,365.63**
12	**Other Equity as per the Balance Sheet**				**7,249.32**
13	**Earnings Per Equity Share (not annualised)**				
	Basic (in INR)	**0.03**	**1.16**	**1.43**	**4.69**
	Diluted (in INR)	**0.03**	**1.16**	**1.43**	**4.69**

Notes

1 The above unaudited financial results for the quarter ended 30th June 2026 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at their respective meetings held on 11th August 2026. The Statutory Auditors have conducted a "Limited Review" of these financial results in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2 The figures for the quarter ended 31st March 2026 are the balancing figures between the audited figures in respect of the full financial year ended 31st March 2026 and the unaudited published figures for nine months ended 31st December 2025.The figures for the corresponding previous periods have been regrouped and reclassified, wherever necessary, to make them comparable.

3 The above unaudited financial results have been prepared in accordance with Indian Accounting Standard 34 "Interim Financal Reporting" (Ind AS 34") precribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

4 Company's business relates to the manufacturing of pharmaceuticals formations, which in context of Indian Accounting Standards 108 (Ind AS 108) as notified under Section 133 of the Companies Act, 2013 is considered as the only segment.

5 The Company has received orders from the Goods and Services Tax authorities, including a demand order raising a GST liability amounting to INR 235.47 Lakhs and another order issued by the Joint Commissioner towards recovery of GST refunds availed during earlier years amounting to INR 331.09 Lakhs, along with applicable interest and penalty. The Company has preferred an appeal against the GST demand of INR 235.47 Lakhs. In respect of the recovery of GST refunds, the Company has obtained a stay for the amount of INR 331.09 Lakhs based on the writ petition before the Honorable Madras High Court. Based on the underlying facts of the cases, applicable legal provisions, judicial precedents and prevailing industry practices, the Company is confident of prevailing against the positions adopted by the GST authorities and accordingly, does not anticipate any adverse financial outcome.

For Bafna Pharmaceuticals Limited

Place : Chennai

Date : 11th August, 2026

BRAHMAYYA & CO. For Identification Only CHARTERED ACCOUNTANTS

BAFNA PHARMACEUTICALS LTD. CHENNAI

S. Hemalatha

Whole Time Director

(DIN: 02714329)

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of Bafna Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Bafna Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Bafna Pharmaceuticals Limited (**the **"Company")**, for the quarter ended 30th June 2026 **(**the **"Statement"),** being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

2. The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. **Emphasis of Matter**

   Attention is invited to Note No. 5 to the Statement, in respect of GST Demand raised by the GST Authorities amounting to INR 235.47 Lakhs and the appeal preferred by the Company before appropriate authorities and another Order received from the Joint Commissioner towards recovery of GST refunds availed by the Company during the earlier years amounting to INR 331.09 Lakhs along with Interest and Penalty thereon, the Company has filed writ petition before the Honourable Madras High Court. As represented by management and based on the underlying facts, the Company is confident of prevailing against the department's position. Accordingly, the Company does not anticipate any adverse financial outcome, and no adjustments are envisaged in the financial results for the quarter ended 30th June 2026.

   Our Conclusion on the Statement is not modified in respect of the above matter.

5. Attention is drawn to the fact that the figures for the quarter ended 31st March 2026 as reported in the Statement are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the previous financial year which were subject to limited review by us.

6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the Statement prepared in accordance with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Brahmayya & Co.,
Chartered Accountants
Firm Registration No. 000511S

BRAHMAYYA & CO. CHENNAI INDIA CHARTERED ACCOUNTANTS

Lokesh Vasudevan
Partner
Membership No:222320
UDIN: 26222320OKEFVD7647

Place: Coonoor
Date: 11th August 2026